Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ARFRP1
REST API REST API
Homo sapiens
ARFRP1 is differentially expressed in 241 experiments: 127 organism parts: prostate, cerebellum, ... (125 more);, 180 disease states: normal, prostate carcinoma, ... (178 more);, 65 cell types 289 cell lines 35 compound treatments and 74 other conditions.
Synonyms ARP, Arp1, ARL18
Orthologs ARFRP_BOVIN (Bos taurus)   arfrp1 (Danio rerio)   Arfrp1 (Rattus norvegicus)   Arfrp1 (Mus musculus)   ARFRP1 (Gallus gallus)   ARL3 (Saccharomyces cerevisiae)   CG7039 (Drosophila melanogaster)   NP_989165.1 (Xenopus laevis)   arfrp1 (Xenopus laevis)   ARFRP1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term GTPase activity, cytoplasm, intracellular, Golgi apparatus, intracellular protein transport, G-protein coupled receptor protein signaling pathway, membrane fraction, signal transducer activity, GTP catabolic process, GTP binding, small GTPase mediated signal transduction, nucleus, nucleotide binding, guanyl nucleotide binding, gastrulation, signal transduction, protein transport
InterPro Term Gprotein_alpha_su, Gtr1_RagA, MIRO-like, SRP_receptor_beta_su, Small_GTPase, Small_GTP-bd_dom, Small_GTPase_SAR1, Small_GTPase_ARF, Small_GTPase_ARF/SAR, Small_GTPase_Rab_type
UniProt Accession B7ZKX7, Q9BQK6, Q9BQK5, Q13795, E9PBT6
Search EB-eye ENSG00000101246
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-MEXP-1251, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, E-GEOD-4717, ... (34 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529, E-GEOD-19639
BT-474
2
E-GEOD-3529, E-GEOD-5823
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
BT474
1
2
E-MTAB-62, E-MEXP-440, E-MTAB-37
human foreskin fibroblast
1
E-GEOD-4219
HCC1187
1
E-MTAB-62
283 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-MEXP-750, E-GEOD-13909, E-GEOD-20677, ... (37 experiments)

Factor Value U/D Experiments
testis - germ cell
2
E-AFMX-5, E-TABM-145
monocyte
1
2
E-GEOD-22373, E-GEOD-11755, E-MEXP-583
stromal cell
1
2
E-GEOD-10797, E-GEOD-1460, E-MEXP-2034
Leukocytes
1
E-GEOD-21909
basal cell
1
E-GEOD-3998
basophil
1
E-GEOD-3982
59 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-6872, E-GEOD-1869, E-GEOD-2466, ... (45 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-GEOD-96, E-MEXP-2034, E-MTAB-62
leiomyosarcoma
2
E-MEXP-1922, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
174 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-GEOD-15205, E-TABM-782, E-GEOD-697, ... (21 experiments)

Factor Value U/D Experiments
none
3
5
E-GEOD-5824, E-MEXP-1958, E-GEOD-2803, E-GEOD-412, E-TABM-782, ... (8 experiments)
control
1
2
E-GEOD-3284, E-GEOD-4006, E-GEOD-5339
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
valproic acid
1
E-GEOD-1615
unknown
1
E-GEOD-7307
M-CSF
1
E-GEOD-5099
29 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-1725 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-4619, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-3325, E-GEOD-22541, E-TABM-147

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-MEXP-563

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, E-GEOD-22593, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-7011, E-MEXP-2657, E-GEOD-12773, E-GEOD-20540 ... (5 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-GEOD-1926, E-GEOD-16363, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254, E-GEOD-17400, E-GEOD-6802

Initial distant metastases
studied in E-GEOD-22541

Irradiate
studied in E-MEXP-2177

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-17636, E-GEOD-2487

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-4922

Processing time: 0.348 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM